Menu
Search
|

Menu

Close
X

Sarepta Therapeutics Inc SRPT.OQ (NASDAQ Stock Exchange Global Select Market)

140.33 USD
-9.32 (-6.23%)
As of Jun 22
chart
Previous Close 149.65
Open 151.19
Volume 4,157,853
3m Avg Volume 506,449
Today’s High 151.50
Today’s Low 140.10
52 Week High 176.44
52 Week Low 32.46
Shares Outstanding (mil) 64.33
Market Capitalization (mil) 3,262.29
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY18
65
FY17
155
FY16
5
FY15
1
EPS (USD)
FY18
-0.547
FY17
-0.798
FY16
-5.452
FY15
-5.192
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
57.46
5.71
Price to Book (MRQ)
vs sector
7.43
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
2.97
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
-47.63
14.38
Return on Equity (TTM)
vs sector
-49.74
16.08

EXECUTIVE LEADERSHIP

Douglas Ingram
President, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Sandesh Mahatme
Executive Vice President, Chief Financial Officer and Chief Business Officer, Since 2017
Salary: $459,252.00
Bonus: $220,441.00
David Howton
Senior Vice President, General Counsel, Corporate Secretary, Since 2012
Salary: $407,176.00
Bonus: $195,445.00
Alexander Cumbo
Senior Vice President, Global Commercial Development, Since 2016
Salary: $314,175.00
Bonus: $152,400.00
Gilmore O'Neill
Senior Vice President, Chief Medical Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

215 1st St Ste 415
CAMBRIDGE   MA   02142-1213

Phone: +1617.2744000

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

SPONSORED STORIES